217 related articles for article (PubMed ID: 30529227)
1. Review: Fluid biomarkers in the human prion diseases.
Thompson AGB; Mead SH
Mol Cell Neurosci; 2019 Jun; 97():81-92. PubMed ID: 30529227
[TBL] [Abstract][Full Text] [Related]
2. Comparison between plasma and cerebrospinal fluid biomarkers for the early diagnosis and association with survival in prion disease.
Abu-Rumeileh S; Baiardi S; Ladogana A; Zenesini C; Bartoletti-Stella A; Poleggi A; Mammana A; Polischi B; Pocchiari M; Capellari S; Parchi P
J Neurol Neurosurg Psychiatry; 2020 Nov; 91(11):1181-1188. PubMed ID: 32928934
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of surrogate CSF biomarkers for Creutzfeldt-Jakob disease in the era of RT-QuIC.
Abu-Rumeileh S; Baiardi S; Polischi B; Mammana A; Franceschini A; Green A; Capellari S; Parchi P
J Neurol; 2019 Dec; 266(12):3136-3143. PubMed ID: 31541342
[TBL] [Abstract][Full Text] [Related]
4. Fluid Biomarkers in Individuals at Risk for Genetic Prion Disease up to Disease Conversion.
Vallabh SM; Mortberg MA; Allen SW; Kupferschmid AC; Kivisakk P; Hammerschlag BL; Bolling A; Trombetta BA; Devitte-McKee K; Ford AM; Sather LE; Duffy G; Rivera A; Gerber J; McManus AJ; Minikel EV; Arnold SE
Neurology; 2024 Jul; 103(2):e209506. PubMed ID: 38896810
[TBL] [Abstract][Full Text] [Related]
5. Prion-specific and surrogate CSF biomarkers in Creutzfeldt-Jakob disease: diagnostic accuracy in relation to molecular subtypes and analysis of neuropathological correlates of p-tau and Aβ42 levels.
Lattanzio F; Abu-Rumeileh S; Franceschini A; Kai H; Amore G; Poggiolini I; Rossi M; Baiardi S; McGuire L; Ladogana A; Pocchiari M; Green A; Capellari S; Parchi P
Acta Neuropathol; 2017 Apr; 133(4):559-578. PubMed ID: 28205010
[TBL] [Abstract][Full Text] [Related]
6. The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias.
Abu-Rumeileh S; Capellari S; Stanzani-Maserati M; Polischi B; Martinelli P; Caroppo P; Ladogana A; Parchi P
Alzheimers Res Ther; 2018 Jan; 10(1):3. PubMed ID: 29368621
[TBL] [Abstract][Full Text] [Related]
7. Seed amplification and neurodegeneration marker trajectories in individuals at risk of prion disease.
Mok TH; Nihat A; Majbour N; Sequeira D; Holm-Mercer L; Coysh T; Darwent L; Batchelor M; Groveman BR; Orr CD; Hughson AG; Heslegrave A; Laban R; Veleva E; Paterson RW; Keshavan A; Schott JM; Swift IJ; Heller C; Rohrer JD; Gerhard A; Butler C; Rowe JB; Masellis M; Chapman M; Lunn MP; Bieschke J; Jackson GS; Zetterberg H; Caughey B; Rudge P; Collinge J; Mead S
Brain; 2023 Jun; 146(6):2570-2583. PubMed ID: 36975162
[TBL] [Abstract][Full Text] [Related]
8. Role of Biomarkers for the Diagnosis of Prion Diseases: A Narrative Review.
Altuna M; Ruiz I; Zelaya MV; Mendioroz M
Medicina (Kaunas); 2022 Mar; 58(4):. PubMed ID: 35454316
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease.
Vallabh SM; Minikel EV; Williams VJ; Carlyle BC; McManus AJ; Wennick CD; Bolling A; Trombetta BA; Urick D; Nobuhara CK; Gerber J; Duddy H; Lachmann I; Stehmann C; Collins SJ; Blennow K; Zetterberg H; Arnold SE
BMC Med; 2020 Jun; 18(1):140. PubMed ID: 32552681
[TBL] [Abstract][Full Text] [Related]
10. NT1-Tau Is Increased in CSF and Plasma of CJD Patients, and Correlates with Disease Progression.
Mengel D; Mok TH; Nihat A; Liu W; Rissman RA; Galasko D; Zetterberg H; Mead S; Collinge J; Walsh DM
Cells; 2021 Dec; 10(12):. PubMed ID: 34944022
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and prognostic value of human prion detection in cerebrospinal fluid.
Foutz A; Appleby BS; Hamlin C; Liu X; Yang S; Cohen Y; Chen W; Blevins J; Fausett C; Wang H; Gambetti P; Zhang S; Hughson A; Tatsuoka C; Schonberger LB; Cohen ML; Caughey B; Safar JG
Ann Neurol; 2017 Jan; 81(1):79-92. PubMed ID: 27893164
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases.
Zerr I; Schmitz M; Karch A; Villar-Piqué A; Kanata E; Golanska E; Díaz-Lucena D; Karsanidou A; Hermann P; Knipper T; Goebel S; Varges D; Sklaviadis T; Sikorska B; Liberski PP; Santana I; Ferrer I; Zetterberg H; Blennow K; Calero O; Calero M; Ladogana A; Sánchez-Valle R; Baldeiras I; Llorens F
Alzheimers Dement; 2018 Jun; 14(6):751-763. PubMed ID: 29391125
[TBL] [Abstract][Full Text] [Related]
13. Rapid amplification of prions from variant Creutzfeldt-Jakob disease cerebrospinal fluid.
Barria MA; Lee A; Green AJ; Knight R; Head MW
J Pathol Clin Res; 2018 Apr; 4(2):86-92. PubMed ID: 29665324
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic Accuracy of Prion Disease Biomarkers in Iatrogenic Creutzfeldt-Jakob Disease.
Llorens F; Villar-Piqué A; Hermann P; Schmitz M; Calero O; Stehmann C; Sarros S; Moda F; Ferrer I; Poleggi A; Pocchiari M; Catania M; Klotz S; O'Regan C; Brett F; Heffernan J; Ladogana A; Collins SJ; Calero M; Kovacs GG; Zerr I
Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32059611
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and Prognostic Value of Plasma GFAP in Sporadic Creutzfeldt-Jakob Disease in the Clinical Setting of Rapidly Progressive Dementia.
Bentivenga GM; Baiardi S; Mastrangelo A; Zenesini C; Mammana A; Rossi M; Polischi B; Capellari S; Parchi P
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791145
[TBL] [Abstract][Full Text] [Related]
16. The cellular prion protein and its derived fragments in human prion diseases and their role as potential biomarkers.
Thüne K; Schmitz M; Villar-Piqué A; Altmeppen HC; Schlomm M; Zafar S; Glatzel M; Llorens F; Zerr I
Expert Rev Mol Diagn; 2019 Nov; 19(11):1007-1018. PubMed ID: 31512940
[No Abstract] [Full Text] [Related]
17. CSF neurogranin as a neuronal damage marker in CJD: a comparative study with AD.
Blennow K; Diaz-Lucena D; Zetterberg H; Villar-Pique A; Karch A; Vidal E; Hermann P; Schmitz M; Ferrer Abizanda I; Zerr I; Llorens F
J Neurol Neurosurg Psychiatry; 2019 Aug; 90(8):846-853. PubMed ID: 31097472
[TBL] [Abstract][Full Text] [Related]
18. Early detection of abnormal prion protein in genetic human prion diseases now possible using real-time QUIC assay.
Sano K; Satoh K; Atarashi R; Takashima H; Iwasaki Y; Yoshida M; Sanjo N; Murai H; Mizusawa H; Schmitz M; Zerr I; Kim YS; Nishida N
PLoS One; 2013; 8(1):e54915. PubMed ID: 23372790
[TBL] [Abstract][Full Text] [Related]
19. Rapid and sensitive RT-QuIC detection of human Creutzfeldt-Jakob disease using cerebrospinal fluid.
Orrú CD; Groveman BR; Hughson AG; Zanusso G; Coulthart MB; Caughey B
mBio; 2015 Jan; 6(1):. PubMed ID: 25604790
[TBL] [Abstract][Full Text] [Related]
20. Prion protein quantification in human cerebrospinal fluid as a tool for prion disease drug development.
Vallabh SM; Nobuhara CK; Llorens F; Zerr I; Parchi P; Capellari S; Kuhn E; Klickstein J; Safar JG; Nery FC; Swoboda KJ; Geschwind MD; Zetterberg H; Arnold SE; Minikel EV; Schreiber SL
Proc Natl Acad Sci U S A; 2019 Apr; 116(16):7793-7798. PubMed ID: 30936307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
